tiprankstipranks

Michael Clayman Insider Profile

11 Followers
Michael Clayman, President & CEO, Director at Flexion Therapeutics, holds 919.90K shares in Flexion Therapeutics (Ticker: FLXN), holds 0.00 shares in Akebia Therapeutics (Ticker: AKBA).
tipranks
Michael Clayman

Michael Clayman
Flexion Therapeutics (FLXN)
President & CEO, Director

Ranked #3,163 out of 78,624 Corporate Insiders

Profitable Transactions

67%
12 out of 18 Profitable Transactions

Average Return

+23.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$10M
100.00%
0.00%
A breakdown of Michael Clayman's holdings

Insider Roles

Flexion Therapeutics
(FLXN)
President & CEO, Director
Akebia Therapeutics
(AKBA)
Director
Roles that Michael Clayman holds in companies

Most Profitable Insider Trade

Stock:
Flexion Therapeutics
(FLXN)
Rating:Informative Buy
Date:May 23, 2016 - May 23, 2017
Return:+84.80%
The most profitable trade made by Michael Clayman

Michael Clayman's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Flexion Therapeutics
Jul 20, 2020
President & CEO, Director
Uninformative Buy
$9.95M
Akebia Therapeutics
Director
$0.00
List of latest transactions for each holding click on a transaction to see Michael Clayman's performance on stock

Michael Clayman insider profile FAQ

What is the percentage of profitable transactions made by Michael Clayman?
The percentage of profitable transactions made by Michael Clayman is 67%.
    What is the average return per transaction made by Michael Clayman?
    The average return per transaction made by Michael Clayman is 23.60%.
      What stocks does Michael Clayman hold?
      Michael Clayman holds: FLXN, AKBA stocks.
        What was Michael Clayman’s latest transaction?
        Michael Clayman latest transaction was an Uninformative Buy of ―.
          What was Michael Clayman's most profitable transaction?
          Michael Clayman’s most profitable transaction was an Informative Buy of FLXN stock on May 23, 2016. The return on the trade was 84.80%.
            What is Michael Clayman's role in Flexion Therapeutics?
            Michael Clayman's role in Flexion Therapeutics is President & CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.